Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine.

abstract：:Alterations in chromatin structure resulting from aberrant DNA methylation and perturbations of the histone code profoundly influence gene expression during pulmonary carcinogenesis. Recent studies indicate that DNA demethylating agents and histone deacetylase (HDAC) inhibitors synergistically induce gene expression a...

journal_title：Seminars in oncology

authors： Schrump DS,Nguyen DM

更新日期：2005-10-01 00:00:00

abstract：:Gemcitabine, a novel nucleoside analog, shows reproducible response rates of 20% and above in single-agent studies in non-small cell lung cancer. In the phase II studies reported, chemotherapy-naive patients received gemcitabine (starting doses, 800 to 1,250 mg/ m2) as a single agent on days 1, 8, and 15 of a 28-day c...

journal_title：Seminars in oncology

authors： Le Chevalier T

更新日期：1996-10-01 00:00:00

abstract：:A trial of combination chemotherapy using mitoxantrone-cyclophosphamide was started in 1983. Sixteen patients with widely metastatic cancer of the breast, including one man, received mitoxantrone, 10 mg/m2 intravenously (IV) over 30 minutes on day 1, followed by cyclophosphamide, 200 mg/m2 by mouth (PO) daily in divid...

journal_title：Seminars in oncology

authors： McDonald DB,Abu-Zahra H,Yoshida S,Binder H

更新日期：1984-09-01 00:00:00

abstract：:Pancreatic cancer is the eighth most common cancer in Europe, accounting for 4.1% of cancer deaths in men and 4.8% in women. Standardized pancreatoduodenectomy and left pancreatectomy are the gold standard for routine surgical treatment of pancreatic cancer. Total pancreatectomy should be reserved for positive pancrea...

journal_title：Seminars in oncology

authors： Pedrazzoli S,Pasquali C,Sperti C

更新日期：2002-12-01 00:00:00

abstract：:Experimental and clinical observations of the proliferation of cancer cells and their responses to cytotoxic drugs already have had an impact on the design of anticancer therapies and it is possible that further understanding of the natural history of tumors will enable better treatments to be developed. This review a...

journal_title：Seminars in oncology

authors： Norton L

更新日期：1997-08-01 00:00:00

abstract：:Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin production in pathologic states such as inflammatory processes and cancer. The enzyme is often overexpressed in premalignant lesions and various cancers, including cancer of the lung. Inhibition of this enzyme with selective COX-2 inhibitors was found to ...

journal_title：Seminars in oncology

authors： Komaki R,Liao Z,Milas L

更新日期：2004-02-01 00:00:00

abstract：:Hypoxic areas are a characteristic property of solid tumors. Hypoxia results from an imbalance between the supply and consumption of oxygen. Major pathogenetic mechanisms for the emergence of hypoxia are (1) structural and functional abnormalities in the tumor microvasculature; (2) an increase in diffusion distances; ...

journal_title：Seminars in oncology

authors： Vaupel P,Kelleher DK,Höckel M

更新日期：2001-04-01 00:00:00

abstract：:Over 50% of patients with small cell lung cancer (SCLC) will develop symptomatic brain metastases during the course of their disease. Results of whole brain radiotherapy, the standard treatment, are rather poor and relapses are frequent. Thus, new modes of therapy are urgently needed for these patients. In this study,...

journal_title：Seminars in oncology

authors： Postmus PE,Smit EF,Berendsen HH,Sleijfer DT,Haaxma-Reiche H

更新日期：1992-04-01 00:00:00

abstract：:This presentation represents consensus recommendations for the treatment of patients with Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the second International Workshop held in Athens, Greece during September 2002. The faculty adopted the following statements for the management of pati...

journal_title：Seminars in oncology

authors： Gertz MA,Anagnostopoulos A,Anderson K,Branagan AR,Coleman M,Frankel SR,Giralt S,Levine T,Munshi N,Pestronk A,Rajkumar V,Treon SP

更新日期：2003-04-01 00:00:00

abstract：:Diffuse large B-cell lymphoma (DLCL) is the most frequently diagnosed subtype of non-Hodgkin's lymphoma (NHL), and more than 50% of cases present in patients over 60 years of age. Although cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) is currently regarded as the gold standard treatment for DLCL, less tha...

journal_title：Seminars in oncology

authors： Coiffier B

更新日期：2002-04-01 00:00:00

abstract：:The treatment of locally advanced carcinoma of the cervix with radiation therapy as a single modality is inadequate, specifically for stage III and IVA disease. While chemotherapy as single-modality therapy is ineffective in advanced cervical cancer, there is some evidence of efficacy when used in combination with rad...

journal_title：Seminars in oncology

authors： Wadler S,Goldberg G,Fields A,Anderson P,Beitler JJ,Sood B,Haynes H,Runowicz C

更新日期：1996-08-01 00:00:00

abstract：:Initial phase I trials of intraperitoneal chemotherapy in ovarian cancer patients demonstrated that a pharmacologic advantage was achieved with the direct instillation of drugs into the peritoneal cavity. Recent trials have reported that approximately 30% of patients who have small-volume residual disease following in...

journal_title：Seminars in oncology

authors： Ozols R

更新日期：1985-09-01 00:00:00

abstract：:Bendamustine has clinical potential in the treatment of low-grade non-Hodgkin's lymphoma (NHL). As a single agent, bendamustine has been used in two studies in patients with relapsed or refractory low-grade NHL. When bendamustine 120 mg/m(2) was given on days 1 and 2, the overall response rate was 73% with complete re...

journal_title：Seminars in oncology

authors： Rummel MJ,Mitrou PS,Hoelzer D

更新日期：2002-08-01 00:00:00

abstract：:Glioblastoma multiforme (GBM) is the most common form of primary malignant brain cancer. Median overall survival (OS) for newly diagnosed patients is only about 12 to 18 months. GBM tumors invariably recur, and there is no widely recognized and effective standard treatment for recurrent GBM. NovoTTF Therapy is a novel...

journal_title：Seminars in oncology

authors： Vymazal J,Wong ET

更新日期：2014-10-01 00:00:00

abstract：:The benefits of radiation therapy (RT) as part of a treatment regimen for cancer must be weighed against the potential risk of harm to the patient and in the pregnant patient, the risk to the developing fetus. Information necessary for determining the potential effects of RT on the developing fetus include the gestati...

journal_title：Seminars in oncology

authors： Greskovich JF Jr,Macklis RM

更新日期：2000-12-01 00:00:00

abstract：:The humanized anti-p185(HER2) monoclonal antibody trastuzumab has been shown to effectively inhibit the growth of HER2-overexpressing breast cancer cells in vivo and in vitro. The treatment of cancer cells with trastuzumab results in downregulation of the HER2 receptor. Further downstream cellular events include the a...

journal_title：Seminars in oncology

authors： Baselga J,Albanell J,Molina MA,Arribas J

更新日期：2001-10-01 00:00:00

abstract：:A phase II study was conducted to evaluate the efficacy and toxicity of lomustine, cytarabine, mitoxantrone and prednisone (CAMP) chemotherapy in doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphomas (NHL). Among 30 patients, the complete remission rate was 27% (duration: 10, 16, 22, 35,...

journal_title：Seminars in oncology

authors： Ruit JB,Löwenberg B,Hagenbeek A,Verhoef GE,Wielenga JJ,Michiels J,Sizoo W

更新日期：1990-12-01 00:00:00

abstract：:Recent changes to the staging of melanoma, coupled with advances in surgical and medical treatment, have resulted in new methods for diagnostic evaluation and reporting of melanocytic lesions by pathologists. This review provides an update on recent changes in evaluation and reporting of primary melanoma, evaluation o...

journal_title：Seminars in oncology

authors： Mathew R,Messina JL

更新日期：2012-04-01 00:00:00

abstract：:Ovarian cancer is a disease that will affect approximately 1% of American women during their lifetime, and contributes to more than 14,000 deaths annually. If not detected early, this disease has a 5-year survival rate of less than 20%. Ovarian cancer develops predominantly from the malignant transformation of a singl...

journal_title：Seminars in oncology

authors： Lynch HT,Casey MJ,Lynch J,White TE,Godwin AK

更新日期：1998-06-01 00:00:00

abstract：:The curative management of gastric adenocarcinoma depends on complete resection of the primary tumor. In patients with lymph node metastases in the resected specimen, the relapse and death rates from recurrent cancer are 70% to 80%. There is continued debate over whether more extensive lymph node dissection (D2) impro...

journal_title：Seminars in oncology

authors： Macdonald JS

更新日期：2003-08-01 00:00:00

abstract：:Traditional cancer diagnostic techniques include assessment of histologic appearance, identification of specific tumor subtypes, tumor grading, assessment of lymph node status, and presence of metastasis. These are useful for initial evaluation, but are limited in their ability to predict response to treatment and/or ...

journal_title：Seminars in oncology

authors： Perez EA,Pusztai L,Van de Vijver M

更新日期：2004-10-01 00:00:00

abstract：:Intra-arterial (IA) therapies for hepatocellular carcinoma (HCC) are considered palliative and should be offered to patients with intermediate-stage multinodular disease and with sufficient liver reserve. They include transarterial chemoembolization (TACE) or bland embolization, transarterial chemotherapy, and transar...

journal_title：Seminars in oncology

authors： Tsochatzis EA,Germani G,Burroughs AK

更新日期：2010-04-01 00:00:00

abstract：:The mainstay of screening for breast cancer is the mammogram. There are several randomized control trials that demonstrate a significant decrease in breast cancer mortality when compared to women without screening mammography included in their care. Digital mammography has improved detection in the dense breast. With ...

journal_title：Seminars in oncology

authors： D'Orsi CJ,Newell MS

更新日期：2011-02-01 00:00:00

abstract：:Acute lymphoblastic leukemia (ALL) 5-year survival rates are approaching 90% in children and 50% in adults who are receiving contemporary risk-directed treatment protocols. Current efforts focus not only on further improving cure rate but also on patient quality of life. Hence, all protocols decrease or limit the use ...

journal_title：Seminars in oncology

authors： Pui CH,Thiel E

更新日期：2009-08-01 00:00:00

abstract：:Transitional cell carcinoma of the urothelium is a highly chemosensitive tumor. Combination chemotherapy can provide both palliation and a modest survival advantage in patients with advanced disease. As shown in a recent phase III trial, the new gold standard should be considered gemcitabine/cisplatin, although toxici...

journal_title：Seminars in oncology

authors： Carles J,Nogué M

更新日期：2001-06-01 00:00:00

abstract：:Dry mouth (xerostomia) is one of the most common complaints following radiation therapy (RT) for head and neck cancers. Notably, RT causes irreparable damage to salivary glands that increases the risk for severe and long-term oral and pharyngeal disorders. Several strategies in the treatment of head and neck cancers h...

journal_title：Seminars in oncology

authors： Ship JA,Hu K

更新日期：2004-12-01 00:00:00

abstract：:Many cytotoxic therapies are available for patients with metastatic breast cancer, but response rates are low and acquired or de novo resistance is virtually universal. Among the agents that are used in the treatment of pretreated metastatic breast cancer are vinorelbine, gemcitabine, nab-paclitaxel, pemetrexed, plati...

journal_title：Seminars in oncology

authors： Cobleigh MA

更新日期：2011-06-01 00:00:00

abstract：:From February 1985 to June 1993, 173 consecutive, previously untreated patients with small cell lung cancer received individualized treatment tailored to disease extent. Almost all patients (14 of 16) with stage I and II disease and 30 patients with operable stage III disease were submitted to surgery preceded or foll...

journal_title：Seminars in oncology

authors： Santoro A,Parra HS,Bidoli P,Angelidou M,Cataldo I,Salvini P,Valagussa P,Milani F,Ravasi G,Bonadonna G

更新日期：1995-02-01 00:00:00

abstract：:Many novel antifolate compounds with unique pharmacologic properties are currently in clinical development. These newer antifolates differ from methotrexate, the most widely used and studied drug in this class, in terms of their lipid solubility and cellular transport affinity, their level of polyglutamation, and thei...

journal_title：Seminars in oncology

authors： Takimoto CH

更新日期：1997-10-01 00:00:00

abstract：:Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-g...

journal_title：Seminars in oncology

authors： Sharma P,Old LJ,Allison JP

更新日期：2007-04-01 00:00:00